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regulator PodJ, which is required for 
swarming motility and synthesis of 
pili and holdfasts (Hinz et al., 2003; 
Viollier et al., 2002). As PodJ also 
contains a coiled-coil region (Lawler 
et al., 2006), perhaps PodJ interacts 
with TipN to establish a localization 
complex at the pole.
Overexpression of TipN-GFP 
causes the formation of new poles 
through cell branching; these new 
poles are competent for flagellum 
assembly and localization of polar 
proteins (Lam et al., 2006). This phe-
notype is reminiscent of the pheno-
type obtained when the expression 
of the actin-like cytoskeletal protein 
MreB is perturbed (Gitai et al., 2004; 
Wagner et al., 2005), suggesting an 
interaction between TipN and MreB. 
Indeed, TipN is required for localiza-
tion of MreB to the site of cell divi-
sion (Lam et al., 2006), suggesting 
the possibility that TipN regulates 
asymmetry and cell division through 
MreB. Given that MreB coordinates 
the synthesis of the cell wall pepti-
doglycan, which is critical for the 
generation and maintenance of bac-
terial cell shape, the role of TipN in 
controlling polarity may ultimately 
be mediated through changes in 
the peptidoglycan. It has been pro-
posed that the differences in pepti-
doglycan composition and growth 
at the septum could help direct pro-
teins involved in generating polarity 
(reviewed in Janakiraman and Gold-
berg, 2004).
Many different bacterial species 
utilize polar localization for func-
tions as diverse as chemoreception, 
adhesion to surfaces, and translo-
cation of effector proteins during 
pathogenesis. Determining whether 
proteins similar to TipN regulate 
polarity in these bacteria becomes 
of obvious interest. The discovery of 
TipN brings the field closer to under-
standing the regulation of polarity, 
whose importance in bacterial cell 
biology is becoming more obvious 
with the finding that many proteins 
localize to the bacterial cell pole.
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Hypertension is a complex disease influenced by multiple genetic and environmental 
factors. The TGF-β signaling pathway has a long recognized role in blood pressure homeo-
stasis. In this issue of Cell, Zacchigna et al. (2006) report that the secreted protein Emilin1 
is a negative regulator of TGF-β signaling. Emilin1 knockout mice display elevated blood 
pressure due to increased TGF-β signaling in the vasculature.Hypertension, generally an increase 
in arterial blood pressure, is a major 
health concern and risk factor for 
other diseases such as myocardial 
infarction and kidney failure. Despite 
its prevalence, the pathogenesis of hypertension is poorly understood. 
What is known is that hypertension 
is multifactorial; both genetic deter-
minants, such as allelic variation in 
genes involved in renal salt absorp-
tion, and environmental factors Cell 124, including diet are implicated in the 
development of this disease (Lifton 
et al., 2001).
Arterial blood pressure is a func-
tion of both the cardiac output—the 
amount of blood pumped out by March 10, 2006 ©2006 Elsevier Inc. 893
figure 1. emilin1 Inhibits TGf-β Processing in the Vasculature
(Left panel) TGF-β is secreted as an inactive proprotein (proTGF-β) into the extracellular space where 
it has to be proteolytic processed by proprotein convertases and then further processed for the 
release of active TGF-β. The extracellular matrix protein Emilin1 binds to proTGF-β and prevents its 
processing. The signal that relieves the inhibition of proTGF-β by Emilin1 is unknown. (Right panel) 
Emilin1-deficient mice have increased levels of active TGF-β in the vasculature. Excessive TGF-β 
signaling (by the activation of signaling pathways that inhibit vascular cell proliferation) results in 
smaller blood vessels and increased peripheral resistance, thereby causing hypertension.the heart—and the resistance in the 
vasculature. Smooth muscle cells 
and endothelial cells lining the vas-
cular walls specify the integrity and 
elasticity of the vessel so that it can 
accommodate changes in systolic 
and diastolic pressure. Changes in 
the vasculature that result in the nar-
rowing of arteries increase peripheral 
resistance and cause hypertension. 
Although this was thought to be due 
to changes in smooth muscle and 
endothelial cells, recently, the extra-
cellular matrix (ECM) in the vascu-
lar wall has been appreciated as a 
critical determinant. Mutations in the 
ECM component elastin have been 
identified in individuals with supraval-
vular aortic stenosis (SVAS), charac-
terized by a narrowing of the ascend-
ing aorta. Mouse models expressing 
a reduced amount of elastin and a 
modified form of fibrillin each have 
abnormalities in arterial walls and 
an increased incidence of hyperten-
sion (Faury et al., 2003). Thus, vessel 
compliance dictated by the ECM also 
modulates blood pressure.894 Cell 124, March 10, 2006 ©2006 ElsTGF-β is central to essential pro-
cesses from embryonic develop-
ment to tumorigenesis (Massague 
et al., 2000). Increased circulating 
TGF-β is found in individuals with 
hypertension. Elevated blood pres-
sure has been attributed to a dual 
action of TGF-β, increasing vasoac-
tive molecules and remodeling blood 
vessel architecture (Ghosh et al., 
2005). Mutations in a TGF-β-related 
signaling pathway (involving the 
bone morphogenetic protein recep-
tor II) are causative in primary pul-
monary hypertension, an autosomal 
dominant disease (Massague et al., 
2000 and references therein).
A new link between the ECM and 
TGF-β in blood pressure homeosta-
sis has been elegantly elucidated in 
this issue of Cell by Zacchigna et 
al. (2006). Using a combination of 
genetic and biochemical techniques, 
they demonstrated that the secreted 
ECM protein elastin microfibril inter-
face-located protein 1 (Emilin1) is a 
negative regulator of TGF-β signaling 
in the vascular wall.evier Inc.Emilin1 is a glycosylated protein 
that belongs to the EMI domain-con-
taining (EDEN) family of ECM pro-
teins. It harbors an N-terminal sig-
nal peptide, a cysteine-rich domain, 
a coiled-coil motif, a collagen-like 
domain, and a C1q-like motif found 
in other ECM proteins. Originally 
isolated from aorta, Emilin1 is inti-
mately associated with elastic fibers 
and microfibrils in blood vessels as 
well as in connective tissue of other 
organs (Colombatti et al., 2000). 
Within cells, Emilin1 is a monomer, 
but, upon secretion, it oligomerizes 
via the formation of disulfide bonds. 
Emilin1 appears to be more slowly 
secreted than other ECM compo-
nents, although the implication of this 
is unclear (Colombatti et al., 2000).
The function of Emilin1 was 
unknown until the gene was dis-
rupted in mice. The mice were viable 
and fertile but showed marked alter-
ations in arterial structure (Zanetti et 
al., 2004). This finding, in conjunction 
with the robust expression of Emilin1 
in the developing heart, prompted 
Zacchigna et al. (2006), to inves-
tigate the role of Emilin1 in the car-
diovascular system. They found that 
Emilin1-deficient animals had ele-
vated systemic blood pressure inde-
pendent of cardiac output. Curiously, 
these animals displayed no defects 
in vascular contractility or mechani-
cal properties, leading the group 
to ask if the increase in peripheral 
resistance was due to vessel size. 
Indeed, Emilin1-deficient mice had 
significantly narrower arteries, which 
caused the hypertensive phenotype.
To determine the mechanism 
by which Emilin1 controlled vessel 
diameter, the authors looked to the 
domains in Emilin1 for clues to its 
function. Whereas the coiled-coil and 
gC1q motifs are involved in multimer-
ization, little was known about the 
cysteine-rich EMI domain. In other 
secreted proteins, these cysteine-
rich motifs have been demonstrated 
to influence growth factor regulation 
(Massague and Chen, 2000). This 
idea in conjunction with the known 
role of TGF-β in blood pressure 
homeostasis prompted the group to 
investigate possible functional inter-
actions between Emilin1 and TGF-β 
receptor ligands. Studies in Xenopus 
embryos and mammalian cell culture 
showed that Emilin1 inhibits TGF-β 
signaling via the interaction of its EMI 
domain with intact proTGF-β.
TGF-β is synthesized as a homodi-
meric inactive proprotein (proTGF-β). 
Once cleaved, the propeptide known 
as the latency-associated protein 
(LAP) remains noncovalently bound 
to TGF-β in a latent complex. This 
association prevents TGF-β from 
interacting with its receptor until LAP 
is removed from the complex (Fig-
ure 1; Annes et al., 2003). Release of 
TGF-β from LAP is achieved through 
the action of thrombospondin-1, inte-
grins, and other proteins.
Zacchigna et al. (2006) showed 
that the extracellular protein Emilin1 
interacts via its EMI domain spe-
cifically with the immature form of 
TGF-β, proTGF-β, but not with the 
latent form of TGF-β bound to LAP. 
Cleavage of proTGF-β was believed 
to occur primarily in the trans-
Golgi by furin convertases, fol-
lowed by secretion of the complex. 
This study reveals that a portion of 
proTGF-β must be secreted prior to 
cleavage and points to a role of Emi-
lin1 upstream of the furin conver-
tases. Thus, Emilin is a novel regu-
lator of TGF-β signaling through its 
ability to interact with the immature 
form of proTGF-β, preventing its 
proteolytic cleavage.
To determine the in vivo signifi-
cance of this interaction, TGF-β sig-
naling was examined in the Emilin1-
deficient background. As predicted 
from the interaction studies, Emi-
lin1-deficient mice showed unop-
posed TGF-β signaling in a number 
of assays. The smaller blood ves-
sel size in Emilin1-deficient mice 
was attributed to the cytostatic role 
of TGF-β. Strikingly, reduction of 
TGF-β gene dosage in Emilin1-defi-
cient mice resulted in the normal-
ization of blood pressure with an 
increase in arterial diameter reducing 
peripheral resistance.This study has identified a novel 
mode of restricting TGF-β availability 
to its receptors via Emilin1. Although 
antagonists to mature ligands of the 
TGF-β family are known (e.g., Cer-
berus, Follistatin, and Noggin; Mas-
sague and Chen, 2000), Emilin1 is 
unique in that it recognizes immature 
TGF-β prior to the cleavage of LAP and 
hence acts as one of the earliest extra-
cellular regulators of TGF-β signaling. 
It is unclear at present why this addi-
tional step is required in the process-
ing of TGF-β in view of the number of 
other mechanisms in place to restrict 
the availability of TGF-β to its receptor. 
Although this regulatory mechanism 
might be limited in vivo to the vas-
culature, Emilin1’s capacity to inhibit 
proTGF-β conversion in heterologous 
systems suggests that this is a general 
means of regulating TGF-β availability. 
More detailed analysis of Emilin1-TGF-β 
interactions in different organ systems 
will reveal the breadth of action of Emi-
lin1 on TGF-β signaling.
In view of the pleiotropic nature of 
TGF-β action, it is perhaps surpris-
ing that Emilin1-deficient mice do 
not have a more severe phenotype 
caused by excessive TGF-β signal-
ing. The authors argue that this may 
be due to functional redundancy 
with the several other Emilin family 
members, the requirement for over-
lapping expression of Emilin1 and 
TGF-β ligands, and the density of 
other mechanisms regulating multi-
ple aspects of TGF-β signaling. It will 
be interesting to determine if tissues 
in the Emilin-deficient mouse other 
than the vasculature and the lung 
demonstrate TGF-β hyperactivation.
TGF-β inhibits cell proliferation by 
reducing c-myc expression and oth-
erwise interfering with the activity of 
G1 cyclin-dependent protein kinases 
(Massague et al., 2000). Although it 
has a cytostatic role and is usually an 
inhibitor of tumorigenesis, TGF-β may 
promote tumorigenesis if its growth 
inhibitory mechanisms are bypassed. 
Indeed, under such circumstances 
TGF-β has been shown to promote Cell 124, Mepithelial-to-mesenchymal transition, 
a hallmark of cancer metastasis (Oft et 
al., 1998). Epithelial-to-mesenchymal 
transition is brought about by down-
regulation of cell-cell adhesion mol-
ecules and an upregulation of ECM-
associated proteins which allow the 
cell to become more invasive. Does 
Emilin1 have a role in tumorigenesis or 
angiogenesis via its role in regulating 
TGF-β? Further analysis of the knock-
out mouse may reveal an impact on 
escape from growth control.
This study has discovered a novel 
player in the TGF-β signaling path-
way and has determined important 
physiological manifestations of this 
interaction. The function of Emilin1 in 
regulating TGF-β signaling raises the 
exciting possibility that the ECM may 
more actively participate in signaling 
by many growth factors than previ-
ously recognized.
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